Ikena Oncology Ikena Oncology
  • Contact
  • Linked
  • Twitter
  • About
    • Our Company
    • Leadership
    • Partners
    • Investors
    • Contact
  • Focus
    • Our Approach
    • Publications
  • Pipeline
    • Development Pipeline
    • IK-930 TEAD Inhibitor
    • IK-007 EP4 Antagonist
    • IK-175 AHR Antagonist
    • IK-412 Kynase Program
  • Careers
    • Culture
    • Job Opportunities
  • Newsroom
    • Press Releases
    • Media Kit
Select Page
    • About
      • Our Company
      • Leadership
      • Partners
      • Investors
      • Contact
    • Focus
      • Our Approach
      • Publications
    • Pipeline
      • Development Pipeline
      • IK-930 TEAD Inhibitor
      • IK-007 EP4 Antagonist
      • IK-175 AHR Antagonist
      • IK-412 Kynase Program
    • Careers
      • Culture
      • Job Opportunities
    • Newsroom
      • Press Releases
      • Media Kit
    • Contact
    • Privacy Policy
    • Terms of Use
    • Linked
    • Twitter

Press releases

Keep up with the latest news from Ikena Oncology.

January 5, 2021

Ikena Oncology Closes $120 Million Series B Financing Led by Omega Funds

November 19, 2020

Ikena Oncology Assembles Multi-Disciplinary Scientific Advisory Board

November 9, 2020

Ikena Oncology to Present New Preclinical Data on AHR Antagonist IK-175 at the Society for Immunotherapy of Cancer’s 2020 Annual Meeting

August 18, 2020

Ikena Oncology Appoints Dr. Sergio Santillana, MD, MSc, MBA as Chief Medical Officer

August 12, 2020

Ikena Oncology Announces Publication in Nature Communications of Preclinical Data Supporting the Therapeutic Potential of AHR Blockade

June 22, 2020

Ikena Oncology Presents New Preclinical Data Highlighting the Anti-Cancer Effects of TEAD Inhibition on the Hippo Signaling Pathway

January 28, 2020

Ikena Oncology Announces Dosing of First Patient in Phase 1 Study Evaluating IK-175 in Patients with Advanced Solid Tumors

December 3, 2019

Kyn Therapeutics Rebrands as Ikena Oncology, Reflecting Next Phase of Growth

12>>

Access our media kit page to view and download assorted corporate assets.

View Media Kit
Footer Logo
Ikena Oncology
645 Summer Street
Suite 101
Boston, MA 02210
  • Privacy Policy
  • Terms of Use
Footer Logo
Ikena Oncology
645 Summer Street
Suite 101
Boston, MA 02210
  • About
  • Our Company
  • Leadership
  • Partners
  • Investors
  • Contact
  • Focus
  • Ikena™ Approach
  • Publications
  • Pipeline
  • Development Pipeline
  • IK-930 TEAD Inhibitor
  • IK-007 EP4 Antagonist
  • IK-175 AHR Antagonist
  • IK-412 Kynase Program
  • Careers
  • Culture
  • Job Opportunities
  • Newsroom
  • Press Releases
  • Media Kit
  • Privacy Policy
  • Terms of Use
  • Linked
  • Twitter
© 2021 Ikena Oncology™